Author

Gabriele Hintzen

Observed name: G. Hintzen

Observed institutions: Novartis (Switzerland), Medizinische Hochschule Hannover, Affimed Therapeutics (Germany), Institute of Immunology, Novartis Institutes for BioMedical Research, Institut für Immunologie

ORCID: 0009-0009-2545-2672

Observed ORCID: 0009-0009-2545-2672

OpenAlex ID: A5084933843

CCR7 Governs Skin Dendritic Cell Migration under Inflammatory and Steady-State Conditions

2004 · Lars Ohl, Mariette Mohaupt, et al. · Immunity · 1,108

PDF

Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells

2006 · Tim Worbs, Ulrike Bode, et al. · The Journal of Experimental Medicine · 732

CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells

2001 · Roland Jacobs, Gabriele Hintzen, et al. · European Journal of Immunology · 493

Thymic T Cell Development and Progenitor Localization Depend on CCR7

2004 · Ana Misslitz, Oliver Pabst, et al. · The Journal of Experimental Medicine · 226

PDF

Induction of Tolerance to Innocuous Inhaled Antigen Relies on a CCR7-Dependent Dendritic Cell-Mediated Antigen Transport to the Bronchial Lymph Node

2006 · Gabriele Hintzen, Lars Ohl, et al. · The Journal of Immunology · 225

PDF

R-Spondin Potentiates Wnt/β-Catenin Signaling through Orphan Receptors LGR4 and LGR5

2012 · Heinz Ruffner, Joëlle Sprunger, et al. · PLoS ONE · 172

PDF

Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue

2007 · Jessica R. Kocks, Ana Clara Marques Davalos-Misslitz, et al. · The Journal of Experimental Medicine · 129

PDF

First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors

2025 · Anthony El-Khoueiry, Omar Saavedra, et al. · Clinical Cancer Research · 28

PDF

Molecular characterization of chronic cutaneous wounds reveals subregion‐ and wound type‐specific differential gene expression

2023 · Shola Michelle Richards, Caroline Gubser Keller, et al. · International Wound Journal · 17

PDF

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.

2023 · Anthony B. El-Khoueiry, Delcia Rivas, et al. · Journal of Clinical Oncology · 11

PDF

Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

2022 · Gabriele Hintzen, Holger J. Dulat, et al. · Frontiers in Oncology · 9

PDF

AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.

2022 · Omar Saavedra Santa Gadea, Eric Christenson, et al. · Journal of Clinical Oncology · 5

Abstract CT149: A phase 1/2a first-in-human study of AFM24, a CD16A/epidermal growth factor (EGFR) bispecific Innate Cell Engager (ICE®), in patients with locally advanced or metastatic EGFR-expressing solid tumors: Preliminary findings from the dose-escalation phase

2022 · Anthony El-Khoueiry, Juanita Lopez, et al. · Cancer Research · 4

A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale.

2022 · Omar Saavedra Santa Gadea, Elena Garralda, et al. · Journal of Clinical Oncology · 4

AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study.

2023 · Anthony B. El-Khoueiry, Daniel Olson, et al. · JCO Global Oncology · 3

PDF

754P A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I

2022 · A.B. El-Khoueiry, J.S. Lopez, et al. · Annals of Oncology · 2

PDF

The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.

2022 · Anthony B. El-Khoueiry, Paul Y. Song, et al. · Journal of Clinical Oncology · 2

729 Targeting epidermal growth factor receptor (EGFR)-expressing solid tumors with AFM24, a novel CD16A bispecific innate cell engager: comprehensive correlative science findings from a phase 1 study

2022 · Gabriele Hintzen, Susanne Wingert, et al. · Journal for ImmunoTherapy of Cancer · 1

PDF

Abstract 1881: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies

2021 · Jens Pahl, Gabriele Hintzen, et al. · Cancer Research · 1

Supplementary Table 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors